ArticleEndocrine2025
Functional study of two siblings with isolated growth hormone deficiency and pituitary MR imaging abnormalities caused by a novel HESX1 variant.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeOur study identifies a novel HESX1 variant in two siblings, resulting in isolated growth hormone deficiency (IGHD) associated with empty sella. To the best of our knowledge, this represents the second recognized mutation within the EH1 repressor domain in HESX1. We explore and interpret the potential mechanism, with the aim of guiding pediatricians comprehend this disorder.
methodsThe clinical data for two Chinese siblings was summarized. Furthermore, multiple sequence alignment and pathogenicity prediction of functional effects through five online algorithms were performed. Additionally, AlphaFold 3 was introduced to predict the three-dimensional protein structure of wild-type HESX1 and its variant. Immunoblotting analysis was also employed to examine changes in protein levels, and a luciferase reporter assay was conducted to further investigate the effects of HESX1 and its variant on PROP1 transcriptional activity.
resultsThis report details two siblings with IGHD and empty sella, caused by a novel Ile23Thr (c.T68C) HESX1 missense mutation in exon 1. This variant was predicted to be disease-causing and to enhance the stability and local contact with E24, as indicated by the 3D prediction model. In the presence of PROP1, the mutant HESX1 exhibited a marked reduction in the suppression of PROP1-mediated activity relative to the wild-type HESX1.
conclusionsThe HESX1 (Ile23Thr) mutation is a partial loss-of-function mutation that attenuates the inhibition of PROP1-mediated activation. This suggests that the mutant can lead to GH deficiency and brain malformation.
Indexed as
Identifiers
40382737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.